BACKGROUND: Differences in outcomes between bioresorbable vascular scaffold (BVS) systems and drug-eluting metal stents (DES) have not been fully evaluated. We aimed to compare clinical and angiographic outcomes in randomised studies of patients with coronary artery disease (CAD), with a secondary analysis performed among registry studies. METHODS: A meta-analysis comparing outcomes between BVS and DES in patients with CAD. Overall estimates of treatment effect were calculated with random-effects model and fixed-effects model. RESULTS: In 6 randomised trials (3818 patients), BVS increased the risk of subacute stent thrombosis (ST) over and above DES (OR 2.14; CI 1.01 to 4.53; p=0.05), with a trend towards an increase in the risk of myocardi...
Aims: The aim of this study was to investigate clinical outcomes of patients at high risk of resteno...
Background: Bioresorbable scaffolds (BRS) were considered to be beneficial for coronary bifurcation ...
Aims: The aim of this meta-analysis was to compare the midterm clinical outcomes of patients treated...
BACKGROUND: Differences in outcomes between bioresorbable vascular scaffold (BVS) systems and drug-e...
Background: Bioresorbable vascular scaffolds (BVS) were designed to reduce the rate of late adverse ...
BACKGROUND: Data regarding long-term clinical outcomes with everolimus-eluting bioresorbable vascula...
Background: Bioresorbable vascular scaffolds (BVS) have been proposed for overcoming the long-term l...
Acute coronary syndromes (ACS) may represent an intriguing clinical scenario for implantation of bio...
Background: Bioresorbable vascular scaffolds (BVS) have emerged as a new treatment option in cardiov...
Background Bioresorbable Vascular Scaffolds (BVS) were introduced to overcome some of the limitation...
bioresorbable vascular scaffold (BVS) versus an everolimus-eluting metallic stent (EES) for percutan...
BackgroundWhile current concerns about bioresorbable scaffolds (BRS) are centered on late or very la...
Abstract Background Coronary bioresorbable scaffolds (BRS) were developed to overcome the limitation...
Aims: The aim of this study was to investigate clinical outcomes of patients at high risk of resteno...
Background: Bioresorbable scaffolds (BRS) were considered to be beneficial for coronary bifurcation ...
Aims: The aim of this meta-analysis was to compare the midterm clinical outcomes of patients treated...
BACKGROUND: Differences in outcomes between bioresorbable vascular scaffold (BVS) systems and drug-e...
Background: Bioresorbable vascular scaffolds (BVS) were designed to reduce the rate of late adverse ...
BACKGROUND: Data regarding long-term clinical outcomes with everolimus-eluting bioresorbable vascula...
Background: Bioresorbable vascular scaffolds (BVS) have been proposed for overcoming the long-term l...
Acute coronary syndromes (ACS) may represent an intriguing clinical scenario for implantation of bio...
Background: Bioresorbable vascular scaffolds (BVS) have emerged as a new treatment option in cardiov...
Background Bioresorbable Vascular Scaffolds (BVS) were introduced to overcome some of the limitation...
bioresorbable vascular scaffold (BVS) versus an everolimus-eluting metallic stent (EES) for percutan...
BackgroundWhile current concerns about bioresorbable scaffolds (BRS) are centered on late or very la...
Abstract Background Coronary bioresorbable scaffolds (BRS) were developed to overcome the limitation...
Aims: The aim of this study was to investigate clinical outcomes of patients at high risk of resteno...
Background: Bioresorbable scaffolds (BRS) were considered to be beneficial for coronary bifurcation ...
Aims: The aim of this meta-analysis was to compare the midterm clinical outcomes of patients treated...